In this episode of Lung Cancer Considered, host Dr. Narjust Florez conducts three mock molecular tumor boards with Dr. Misako Nagasaka and Dr. Biagio Ricciuti, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion addresses the question, “How do we get the right molecular answer, at the right time, for the right patient?”
Guests:
Misako Nagasaka, MD, PhD
Associate Clinical Professor
University of California, Irvine
Biagio Ricciuti, MD, PhD
Thoracic Medical Oncologist, Dana-Farber Cancer Institute
Faculty, Harvard School of Medicine
New Zealand